Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0085580 (essential hypertension)
 14,686 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

1. Haemodynamic changes during the onset of the antihypertensive action of pindolol, 10 mg twice daily, and propranolol, 80 mg three times daily, were studied for 24 h in two groups of 10 patients with uncomplicated essential hypertension. 2. Baseline haemodynamics were not different between the two groups. 3. Pindolol, with considerable intrinsic sympathomimetic activity (ISA) exerted its maximal antihypertensive efficacy within 3-4 after dosing (-15 +/- 3%, mean +/- s.e. mean, P less than 0.001). This effect was maintained for 24 h. 4. After propranolol, which is devoid of ISA, arterial pressure fell more gradually, but after 24 h the two drugs shared an equal antihypertensive effect. 5. Cardiac output rose after pindolol by 16 +/- 5% (P less than 0.01). It decreased transiently by 16 +/- 6% (P less than 0.01) 1-4 h after propranolol. At that time vascular resistance had risen by 18 +/- 5% (P less than 0.001). 6. The onset of the antihypertensive action of the two drugs was associated with reductions in vascular resistance. Since reflex vasoconstriction did not occur after pindolol, vascular resistance was always lower on this drug than on propranolol (-29 +/- 4%, P less than 0.001 vs -15 +/- 5%, P less than 0.01). 7. Cardiac filling pressures, pulmonary artery pressure and pulmonary vascular resistance did not change after pindolol but they rose after propranolol. 8. During the onset of the vasodilator and antihypertensive effects of the two beta-adrenoceptor blockers heart rate, stroke volume and cardiac output rose, despite cardiac beta-adrenoceptor blockade, suggesting a reduction of parasympathetic tone and an increase in venous return.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Comparison of the onset of the antihypertensive action of pindolol and propranolol. A 24 h haemodynamic study. 332 34

The antihypertensive action of chronic beta-blockade, with simultaneous reduction of beta-receptor activity at the medullary, cardiac and renal levels, is complex. An integrated explanation is offered by stressing the importance of the whole-body balance between sodium and noradrenaline. Evidence was provided in an eleven week lasting study in patients with essential hypertension, where chronic beta-blockade was performed by increasing doses of Pindolol (10--20 mg/die). While urinary sodium and noradrenaline showed only small changes, the correlation between blood pressure and the sodium/noradrenaline quotient reversed significantly. The altered correlation is interpreted as the common result of the different hypotensive actions of chronic beta-blockade, with special regard to the renal component. Thus, pressure normalisation in essential hypertension during chronic beta-blockade is achieved by an adjustment of the imbalance between whole-body sodium and whole-body noradrenaline.
 ...
PMID:Balance of noradrenaline and sodium during chronic beta-receptor blockade in patients with essential hypertension. 610 59

Eight out-patients with essential hypertension participated in a comparative, placebo-controlled study with a cross-over design. Pindolol and propranolol were administered orally in doses of 20.0 +/- 3.13 mg/d (mean +/- SEM) and 125.0 +/- 19.17 mg/d respectively. Pindolol reduced mean blood pressure by 11.9 mmHg; pre-ejection period index by 8.1 msec; total peripheral resistance by 3.1 mmHg min/L; and limb vascular resistance by 3.28 mmHg min 100 g/ml. Heart rate, cardiac output, plasma renin activity and urinary norepinephrine excretion rate were not altered by pindolol. Propranolol reduced mean blood pressure by 14.0 mmHg; heart rate by 9.1 beats/min; cardiac output by 0.57 L/min; limb blood flow by 1.06 ml/100 g.min; and plasma renin activity by 1.44 ng/ml/h; and increased pre-ejection period index by 8.7 msec. Total peripheral resistance, limb vascular resistance and urinary norepinephrine excretion rate were not altered by propranolol. It was concluded that: (1) the drugs, pindolol and propranolol, are equally effective as antihypertensive agents; (2) heart function and plasma renin activity are decreased by propranolol and unaltered by pindolol; (3) total peripheral resistance is decreased by pindolol and unaltered by propranolol; and (4) these findings may be explained by the intrinsic sympathomimetic activity exhibited by pindolol only.
 ...
PMID:A comparative study on the effects of pindolol and propranolol on systemic and cardiac haemodynamics in hypertensive patients. 638 72

Atenolol, Pindolol and Propranolol in single daily doses administered to 18 selected patients with mild essential hypertension achieved adequate control of blood pressure. Chlorothiazide had been initially administered twice a day without full control of blood pressure and this diuretic therapy was continued unaltered throughout the study. Methacholine challenge testing of respiratory function was performed during the placebo phase and with each beta adrenoreceptor-blocking drug. In the 18 non-asthmatic patients, the reduction in FEV1, was significant only for propranolol therapy when compared to placebo. Each beta adrenoreceptor-blocking drug was associated with small, but significant, increases in fasting plasma triglyceride concentrations and suppression of fasting immuno-reactive glucagon concentrations.
 ...
PMID:Beta adrenoreceptor-blocking drugs once daily in essential hypertension: a comparison of propranolol, pindolol and atenolol. 701 82

Pulmonary function was measured serially in two separate randomized trials of pindolol in the treatment of essential hypertension. Patients with overt obstructive airways disease were excluded. In study 1, 131 hypertensive patients were randomized to placebo (31) and 15 mg (33), 30 mg (33), and 60 mg (34) of pindolol. Pulmonary function was measured before and at weeks 8 and 15 of active medication. Bronchospasm--a 20% increase in forced expiratory volume in 1 second (FEV1) after isoprenaline--developed in three patients on active treatment and one on placebo. In eight patients on pindolol and one on placebo, bronchospasm ceased. Compared to placebo, no deterioration in pulmonary function occurred with pindolol and in three tests--maximum voluntary ventilation (MVV) (L/min), MVV%, midexpiratory flow rate (MEFR) (L/min)--significant improvement occurred. In study 2, 14 hypertensive patients were randomized to pindolol (mean dose 50 mg/day), 15 to propranolol (mean 360 mg/day), and 14 to chlorthalidone (mean 107 mg/day). Pulmonary function was measured after 3 weeks of placebo and again after 6 weeks of active treatment. While propranolol produced slight deterioration in pulmonary function, pindolol and chlorthalidone produced slight but significant improvement (p less than 0.05) with maximum MEFR (L/sec). Pulmonary function tests measured after isoprenaline were significantly worse in patients on propranolol compared to those on placebo, but were unchanged in patients on pindolol or chlorthalidone. The conclusions are: (1) Pindolol in antihypertensive doses does not produce airways obstruction and some improvement in pulmonary function may occur. (2) In comparable doses, pindolol has a positive effect on pulmonary function and propranolol a negative effect which, when summated, is statistically significant. (3) Propranolol, but not pindolol, appears to block the bronchodilator effects of isoprenaline. The lack of pulmonary function impairment may be due to intrinsic sympathomimetic activity properties of pindolol.
 ...
PMID:Pulmonary function in hypertensive patients treated with pindolol: a report of two studies. 704 80

36 out of 52 patients with essential hypertension, whose blood pressure was not normalized with pindolol 15 mg per day, were treated with 30 mg per day for four to six weeks. Pindolol was administered in random order, either as 15 mg twice daily or as one 30 mg retard tablet once daily. Blood pressure was lowered from mean pretreatment levels of 174/111 mmHg to 149/98 mmHg by 15 mg b.d., and to 145/97 mmHg by 30 mg retard. In five patients diurnal variations in blood pressure and plasma pindolol levels were determined. At all times during the day blood pressure was at least well controlled by 30 mg retard as by 15 mg b.d. Plasma concentration maxima were similar with both forms, but a higher concentration was maintained for a longer time after the retard tablet. Pindolol 30 mg was well tolerated and the incidence of side effects was lower than during treatment with 15 mg b.d. Thus, patients requiring high doses of pindolol for control of hypertension can safely and conveniently be treated with a single tablet of 30 mg pindolol retard.
 ...
PMID:Simplified antihypertensive therapy with pindolol retard. 707 49


<< Previous 1 2